Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL~* HCV genotype 3~* Chronic HCV infection (≥ 6 months)~* Females of childbearing potential must have a negative serum pregnancy test~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV) that may interfere with subject treatment, assessment or compliance with the protocol~* Screening ECG with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at Screening~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL 12 Weeks (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks
- SOF+RBV 24 Weeks (Type: EXPERIMENTAL): SOF+RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).